NASDAQ:LPDX

(LPDX) (LPDX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LPDX stock logo

About (LPDX) Stock (NASDAQ:LPDX)

LipoScience, Inc. is a vitro diagnostic company. The Company’s diagnostic test, the nuclear magnetic resonance (NMR) LipoProfile test, directly measures the number of low density lipoprotein (LDL), particles in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. The Company’s Vantera system is the Company's automated clinical analyzer. As of January 25, 2013, over eight million NMR LipoProfile tests were ordered. The Vantera system is its automated clinical analyzer. In August 2012, the Company received Food and Drug Administration (FDA) clearance to market the Vantera system commercially to laboratories.

LPDX Stock News Headlines

Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
LPDX Historical Data
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
See More Headlines
Receive LPDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (LPDX) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2014
Today
4/25/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LPDX
CUSIP
53630M10
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

LPDX Stock Analysis - Frequently Asked Questions

How were (LPDX)'s earnings last quarter?

(LPDX) (NASDAQ:LPDX) announced its quarterly earnings results on Wednesday, November, 12th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The biotechnology company had revenue of $8.56 million for the quarter, compared to analysts' expectations of $8.80 million. During the same period in the previous year, the business posted ($0.31) earnings per share.

What other stocks do shareholders of (LPDX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (LPDX) investors own include Altaba (AABA), Global Sources Ltd. Bermuda (GSOL), Alcoa (AA), Agios Pharmaceuticals (AGIO), AerCap (AER), AEGR (AEGR), Aegon (AEG) and Acorda Therapeutics (ACOR).

This page (NASDAQ:LPDX) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners